Balance Sheet

v3.10.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Dec. 31, 2018
Mar. 31, 2018
Current Assets    
Cash $ 241,571 $ 60,934
Accounts receivable, net of allowance of nil and $887 at December 31, 2018 (unaudited) and March 31, 2018, respectively 17,822 12,386
Inventory 70,105 29,074
Prepaids and other current assets 46,756 124,455
Total Current Assets 376,254 226,849
Property and equipment, net 3,563 4,441
Equity investments 873,300 468,537
Deposit on the acquisition of Trace Analytics, Inc. 550,000
Other asset 5,500 5,500
TOTAL ASSETS 1,808,617 705,327
Current Liabilities    
Accounts payable 33,131 21,846
Accrued expenses 150,246 14,039
Total Current Liabilities 183,377 35,885
Stockholders' Equity    
Preferred stock; $0.00001 par value; 5,000,000 shares authorized; none issued and outstanding at December 31, 2018 (unaudited) and March 31, 2018
Common stock; $0.00001 par value; 200,000,000 shares authorized; 11,597,110 and 10,499,610 issued and outstanding at December 31, 2018 (unaudited) and March 31, 2018, respectively 116 105
Additional paid in capital 4,960,791 3,054,297
Common stock to be issued, 1,656,500 and 263,000 shares at December 31, 2018 (unaudited) and March 31, 2018, respectively 1,982,352 526,000
Accumulated deficit (5,299,634) (2,901,933)
Total Applied BioSciences Corp. Stockholders' Equity 1,643,625 678,469
Non-controlling interest (18,385) (9,027)
Total Stockholders' Equity 1,625,240 669,442
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 1,808,617 $ 705,327

Source